Market Insight from

New coronavirus variant causing concern as cases spike in South Africa

South Africa has reported a new variant of Covid-19, 501.V2, and a corresponding sharp rise in case numbers in the last month. This new strain is independent of the UK’s new strain.

However, the mutation and rise in cases in South Africa has gone largely unnoticed while extensive coverage was given to the new UK variant, SARS-CoV-2 (B.1.1.7), which is believed to have caused the spike of cases in the UK. The lack of attention being given to the South Africa variant may be a problem, as recent findings have shown that the South African variant is now considered more infectious than the UK variant.

South Africa experienced a decline in new Covid-19 cases after the initial first wave. However, this second wave shows a foreboding trajectory for the number of Covid-19 daily confirmed cases (Figure 1).

Tulio de Oliveira, director of KwaZulu-Natal Research and Innovation Sequencing Platform at the University of KwaZulu-Natal, and Francois Balloux, professor at University College London, have suggested that this spike in cases might be caused by the new variant more resistant to vaccines, but this has not been confirmed.

According to Balloux, the South African variant shows more spike protein mutation than the UK variant, which might help the virus escape the immune protection provided by vaccination or prior infection.

As mapping of this strain is difficult in real-time, South Africa needs support from the international community with genetic sequencing, mapping and further analysis of this variant. It also needs to be confirmed if the Pfizer and Moderna vaccines are effective against this variant of the virus.

Mutation in a virus is to be expected, especially in a virus that is widely prevalent. However, the increased contagiousness of this new variant is cause for concern. Researchers suspect that variant 501.V2 is more infectious based on its dominance compared with other strains of SARS-CoV-2.

This variant is expected to be the most prevalent in Johannesburg and other surrounding provinces in South Africa. A similar pattern was reported in the UK, where the B.1.1.7 strain quickly dominated the other strains in London and the surrounding areas.

On a positive note, vaccination is underway in Europe and North America. Unfortunately, it is unclear if the currently available vaccines will be effective against these strains. As such, at-risk countries should exercise caution. In the meantime, travel from South Africa needs to be restricted until researchers have a clearer understanding of the variant’s contagiousness and antibody resistance.

Figure 1: Covid-19 Daily New Cases, South Africa, 6 March 2020– 6 January 2021.

For pharmaceutical industry data, comment and analysis, visit GlobalData's Pharmaceuticals Intelligence Centre.

Go to article: Home | Catching the next Covid-19 variantGo to article: In this issueGo to article: ContentsGo to article: HOF Sonderanlagenbau Company Insight Go to article: HOF SonderanlagenbauGo to article: BriefingGo to article: Industry newsGo to article: The pharma industry briefingGo to article: Covid-19 executive briefing by GlobalDataGo to article: Mimotopes Company Insight Go to article: MimotopesGo to article: Mettler Toledo Company InsightGo to article: Data Integrity Solutions – METTLER TOLEDOGo to article: CommentGo to article: New coronavirus variant causing concern as cases spike in South AfricaGo to article: Teva and MedinCell looking to enter LAI schizophrenia marketGo to article: Lack of injectable anti-HIV therapies in the Japanese marketGo to article: Prevention of thrombosis in Covid-19 patientsGo to article: T2D therapy accepted into FDA Emerging Technology ProgramGo to article: Owen Mumford Company Insight Go to article: Owen MumfordGo to article: ButterworthGo to article:  Molnár-Institute Company Insight Go to article: Molnar-InstituteGo to article: In DepthGo to article: Enter Amazon Pharmacy: the beginning of a great online pharmacy fight?Go to article: Covid-19 vaccines have made treating racism in medicine even more urgentGo to article: Could Covid-19 give pharma the chance for the ultimate image makeover?Go to article: Delivering a billion doses with the UK VMICGo to article: Tackling the ‘silent pandemic’ of AMR: WHO launches the Global Leaders GroupGo to article: Saxenda: profiling the first NHS weight loss drug for a decadeGo to article: How real-time genomic surveillance could spot new Covid-19 variantsGo to article: A new hope for slowing disability in MSGo to article: DatwylerGo to article: Datwyler Company Insight Go to article: ACG WorldwideGo to article: Gemini Data LoggersGo to article: In DataGo to article: Inside the dealGo to article: Deals analysisGo to article: The pharma industry key listGo to article: Global markets and indicesGo to article:  Macro-economic indicatorsGo to article: Macro-economic indicators (page 2)Go to article: EventsGo to article: Next issue